Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (1894)	8/28/2000 7:25:14 PM
From: scaram(o)uche	Respond to of 4974

the first seven months of 2000, total public offerings reaped about $9.3 billion, with IPOs pulling in close to $4.4 billion of that. These five IPOs (Evotec, Symyx, Tularik, Caliper,Maxygen)started the biggest public financing wave that the biotechnology sector has ever witnessed Serious money. Here's more......... Monday August 28, 6:43 pm Eastern Time Press Release SOURCE: Rosetta Inpharmatics, Inc. Rosetta Inpharmatics, Inc. Announces Exercise of Over-Allotment Option In Connection With Initial Public Offering KIRKLAND, Wash., Aug. 28 /PRNewswire/ -- Rosetta Inpharmatics, Inc. (Nasdaq: RSTA - news) today announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 1,080,000 shares of common stock. The company's completion of the offering results in the total sale of 8,280,000 shares for $115,920,000. The public offering was lead managed by Lehman Brothers and co-managed by Lazard Freres & Co. LLC, Prudential Vector Healthcare Group, a unit of Prudential Securities, and Fidelity Capital Markets, a division of National Financial Services Corporation. (snip)